Ditchcarbon
  • Contact
  1. Organizations
  2. Zymeworks Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Zymeworks Inc. Sustainability Profile

Company website

Zymeworks Inc., a leading biotechnology company headquartered in the United States, specialises in the development of innovative therapeutic solutions for cancer and other serious diseases. Founded in 2003, Zymeworks has established itself as a pioneer in the field of protein engineering, particularly through its proprietary ZymeLink™ and Zymeworks' Azymetric™ platforms, which enable the creation of multifunctional therapeutics. With a strong presence in North America and expanding operations in Europe and Asia, Zymeworks focuses on advancing its pipeline of bispecific antibodies and antibody-drug conjugates. The company has achieved significant milestones, including strategic partnerships with major pharmaceutical firms, positioning itself as a key player in the biopharmaceutical industry. Zymeworks' commitment to innovation and excellence continues to drive its success in delivering unique, targeted therapies that address unmet medical needs.

DitchCarbon Score

How does Zymeworks Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Zymeworks Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

38%

Let us know if this data was useful to you

Zymeworks Inc.'s reported carbon emissions

Zymeworks Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Zymeworks may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and climate commitments. However, without specific emissions data or reduction initiatives, it is challenging to assess Zymeworks' position relative to its peers. As the industry evolves, it is likely that Zymeworks will need to consider implementing and communicating its climate strategies to align with broader environmental goals.

How Carbon Intensive is Zymeworks Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Zymeworks Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Zymeworks Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Zymeworks Inc. is in US, which has a low grid carbon intensity relative to other regions.

Zymeworks Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Zymeworks Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Zymeworks Inc.'s Emissions with Industry Peers

Mirati Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Genscript Biotech

US
•
Research and development services (73)
Updated about 1 month ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Distributed Bio, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

AbCellera

CA
•
Pharmaceutical Preparation Manufacturing
Updated 30 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251210.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy